Sen-Jam 11-4-2025 News & Company Updates Sen-Jam Pharmaceutical Takes the Stage at European Biopharma Obesity Innovation Forum
Sen-Jam 27-5-2025 News & Company Updates Behind the Breakthrough: Strategic Insights from Sen-Jam's Executive Leadership and Destum Partners
Sen-Jam 23-1-2025 News & Company Updates Patent Milestone and Stability Data Strengthen Licensing Value of SJP-002C
Sen-Jam 11-3-2025 News & Company Updates Sen-Jam Pharmaceutical Welcomes Immunology and Infectious Disease Expert Dr. Ashley St. John to its Scientific Advisory Board
Sen-Jam 10-2-2025 News & Company Updates Sen-Jam Pharmaceutical Engages Destum Partners to Source Strategic Partnerships for SJP-001 & SJP-002C
Sen-Jam 25-7-2025 News & Company Updates Sen-Jam Pharmaceutical Answers Surgeon General's Alarm with a New Therapeutic Aimed at Tackling Alcohol Related Risks
Sen-Jam 15-4-2025 News & Company Updates Sen-Jam Pharmaceutical Announces Preliminary Results from Phase 2 Clinical Trials of SJP-002C for Upper Respiratory Infections/COVID-19
Sen-Jam 14-3-2025 News & Company Updates Sen-Jam Pharmaceutical: Revolutionizing Inflammatory Care with Proprietary PAIR Technology for Metabolic Balance and Inflammation Resolution
Sen-Jam 09-5-2025 News & Company Updates Sen-Jam Pharmaceutical Files Groundbreaking Patent for Novel Therapeutic Approach to Address Obesity and Metabolic Disorders
